Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00514215 · ClinicalTrials.gov registry record · Phase 2
Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer
A Phase 2 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00514215 is a Phase 2 study that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 8 participants.
The verdict
NCT00514215, a Phase 2 study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
RATIONALE: Cryotherapy kills tumor cells by freezing them. Giving an injection of GM-CSF before cryotherapy and inhaling GM-CSF after cryotherapy may interfere with the growth of tumor cells and shrink the tumor. Giving cryotherapy together with GM-CSF may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cryotherapy together with GM-CSF works in treating patients with lung metastases or primary lung cancer.
Interventions
- PROCEDURE biopsy
- OTHER flow cytometry
- BIOLOGICAL sargramostim
- OTHER immunoenzyme technique
- PROCEDURE cryosurgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2006-01 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00514215
The ClinicalTrials.gov registry entry for NCT00514215 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which biopsy is the first listed.
NCT00514215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00514215 about?
NCT00514215 is a clinical study titled "Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer". RATIONALE: Cryotherapy kills tumor cells by freezing them. Giving an injection of GM-CSF before cryotherapy and inhaling GM-CSF after cryotherapy may interfere with the growth of tumor cells and shrink the tumor. Giving cryotherapy together with GM-CSF may kill more tumor cells. PURPOSE: This phase...
What is the current status of trial NCT00514215?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2006-01. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00514215?
The interventions under investigation include: biopsy (PROCEDURE), flow cytometry (OTHER), sargramostim (BIOLOGICAL), immunoenzyme technique (OTHER), cryosurgery (PROCEDURE).
Who is sponsoring clinical trial NCT00514215?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.